Can a cancer drug wipe out hidden tumor cells after surgery?
NCT ID NCT03832569
First seen Mar 06, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This study tests the safety and effectiveness of pembrolizumab, an immunotherapy drug, in 17 adults with MSI-H solid tumors who still have cancer DNA in their blood after surgery. Participants receive the drug every 3 weeks for up to 12 months. The main goal is to see if the drug can clear the cancer DNA from the blood, which might help prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (a drug that helps the immune system fight cancer)
What this could lead to
If it works, this could point toward a way to stop certain cancers from coming back after surgery by using the immune system to clear remaining tumor cells.
What could go wrong
This is a very small, early-phase trial with only 17 participants, so results may not apply to everyone. The drug can cause serious side effects, and it's not yet known if it will actually prevent cancer recurrence.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.